ATE204173T1 - Verwendung von 1-beta-d-ribofuranosyl-1,2,4- triazol-3-carboxamid (ribavirin) zur herstellung eines medikaments für die behandlung von arboviren - Google Patents

Verwendung von 1-beta-d-ribofuranosyl-1,2,4- triazol-3-carboxamid (ribavirin) zur herstellung eines medikaments für die behandlung von arboviren

Info

Publication number
ATE204173T1
ATE204173T1 AT94118300T AT94118300T ATE204173T1 AT E204173 T1 ATE204173 T1 AT E204173T1 AT 94118300 T AT94118300 T AT 94118300T AT 94118300 T AT94118300 T AT 94118300T AT E204173 T1 ATE204173 T1 AT E204173T1
Authority
AT
Austria
Prior art keywords
ribofuranosyl
carboxamide
triazole
arboviruses
ribavirin
Prior art date
Application number
AT94118300T
Other languages
English (en)
Inventor
Robert Angus Smith
Humberto Fernandes
Original Assignee
Vira Tek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24673430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE204173(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vira Tek Inc filed Critical Vira Tek Inc
Application granted granted Critical
Publication of ATE204173T1 publication Critical patent/ATE204173T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT94118300T 1984-10-29 1985-04-16 Verwendung von 1-beta-d-ribofuranosyl-1,2,4- triazol-3-carboxamid (ribavirin) zur herstellung eines medikaments für die behandlung von arboviren ATE204173T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66625284A 1984-10-29 1984-10-29

Publications (1)

Publication Number Publication Date
ATE204173T1 true ATE204173T1 (de) 2001-09-15

Family

ID=24673430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94118300T ATE204173T1 (de) 1984-10-29 1985-04-16 Verwendung von 1-beta-d-ribofuranosyl-1,2,4- triazol-3-carboxamid (ribavirin) zur herstellung eines medikaments für die behandlung von arboviren

Country Status (18)

Country Link
EP (3) EP0383361A3 (de)
JP (1) JPH0713019B2 (de)
KR (1) KR860003018A (de)
AT (1) ATE204173T1 (de)
AU (1) AU584333B2 (de)
BE (1) BE902199A (de)
CA (1) CA1261265A (de)
DD (1) DD261094A5 (de)
DE (3) DE3588232T2 (de)
ES (1) ES8704962A1 (de)
FR (1) FR2572286B1 (de)
GB (1) GB2166050B (de)
LU (1) LU85854A1 (de)
NL (1) NL300083I1 (de)
NZ (1) NZ212510A (de)
PH (1) PH22534A (de)
PT (1) PT81387B (de)
ZA (1) ZA858237B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE126696T1 (de) * 1985-12-23 1995-09-15 Hutchinson Fred Cancer Res Regulierung der retroviralen replikation, infektion und pathogenese.
JP2792246B2 (ja) * 1991-01-31 1998-09-03 信越半導体株式会社 単結晶棒クランプ位置決め治具及びこれを用いた単結晶棒クランプ位置決め方法
PL364699A1 (en) * 1999-01-29 2004-12-13 Icn Pharmaceuticals, Inc. Modulation of immune response by ribavirin
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US7132453B2 (en) * 2002-03-15 2006-11-07 Vanderbilt University Method of using prostacyclin to treat respiratory syncytial virus infections
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
US20170128482A1 (en) 2014-06-23 2017-05-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
US20170151272A1 (en) 2014-06-23 2017-06-01 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A novel pharmaceutical composition of sofosbuvir and ribavirin
EA201692507A1 (ru) 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические комбинации софосбувира и рибавирина
JP2018076280A (ja) * 2016-10-28 2018-05-17 国立大学法人 大分大学 ジカウイルス感染症治療用医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AR205339A1 (es) * 1973-03-12 1976-04-30 Icn Pharmaceuticals Sintesis de 1,2,4-triazolo-3-carboxamidas utiles como agentes antivirales
WO1983003383A1 (en) * 1982-03-29 1983-10-13 Liposome Co Inc Stable plurilamellar vesicles

Also Published As

Publication number Publication date
ES548303A0 (es) 1987-04-16
JPH0713019B2 (ja) 1995-02-15
ZA858237B (en) 1988-02-24
DE181050T1 (de) 1986-12-18
CA1261265A (en) 1989-09-26
HK1010985A1 (en) 1999-07-02
DE10299005I1 (de) 2002-05-08
LU85854A1 (fr) 1985-12-16
NL300083I1 (nl) 2002-05-01
DE3588232D1 (de) 2001-09-20
AU584333B2 (en) 1989-05-25
EP0643970B1 (de) 2001-08-16
EP0181050A3 (de) 1987-10-21
PT81387B (pt) 1987-11-11
DE10299005I2 (de) 2004-07-01
PT81387A (en) 1985-11-01
GB2166050A (en) 1986-04-30
FR2572286B1 (fr) 1990-03-23
EP0181050A2 (de) 1986-05-14
GB8509689D0 (en) 1985-05-22
AU4180785A (en) 1986-05-08
BE902199A (fr) 1985-07-31
PH22534A (en) 1988-10-17
JPS61109723A (ja) 1986-05-28
GB2166050B (en) 1989-08-16
EP0643970A3 (de) 1997-07-09
EP0643970A2 (de) 1995-03-22
NZ212510A (en) 1989-04-26
DE3588232T2 (de) 2002-06-13
FR2572286A1 (fr) 1986-05-02
EP0383361A3 (de) 1993-06-16
KR860003018A (ko) 1986-05-19
DD261094A5 (de) 1988-10-19
ES8704962A1 (es) 1987-04-16
EP0383361A2 (de) 1990-08-22

Similar Documents

Publication Publication Date Title
DE69508192D1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
ATE132747T1 (de) Sprays zur behandlung von infektionen des tractus respiratorius
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
ATE204173T1 (de) Verwendung von 1-beta-d-ribofuranosyl-1,2,4- triazol-3-carboxamid (ribavirin) zur herstellung eines medikaments für die behandlung von arboviren
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
EP0224596A4 (de) Verwendung von aus Schisandrae Fructus extrahierten Dibenzocyclooctadien-Lignanen zur Herstellung eines Arzneimittels für die Behandlung von Leberschwäche.
DE3578374D1 (de) Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen.
EP0757697A4 (de) Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69626276D1 (de) Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE69531298D1 (de) Behandlung von influenzavirus-infektion unter verwendung von antiviralen acylierung/palmitylierung von hemagglutinin hemmen
DE69529070D1 (de) Verwendung von 5,6-o-benzyliden-l-ascorbinsäure oder deren salze zur herstellung eines medikaments zur behandlung von hiv
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
TR199901998T2 (xx) 9,10-sekokolesta-5,7,10(19)-triyen-1,3-diyol veya alfakasidol�n kullan�m�.
DE69619048D1 (de) Verwendung von Oligosacchariden, welche die Adhäsion an Lewis-x Glycolipid hemmen, zur Herstellung eines Medikaments für die Behandlung von Katarakt
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
ATE98612T1 (de) Verfahren zur behandlung von einer waesserigen loesung, die insbesondere salpetersaeure und flusssaeure enthaelt.
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.
ATE94558T1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.